Trial Profile

Everolimus and temozolomide as first-line treatment in advanced gastrointestinal neuroendocrine carcinoma (G3) with a Ki67 of 20-55%

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 06 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Everolimus (Primary) ; Temozolomide (Primary)
Indications Gastrointestinal cancer; Neuroendocrine carcinoma
Focus Therapeutic Use

Most Recent Events

18 Dec 2019 Status changed from active, no longer recruiting to completed.
17 Nov 2019 This trial has been completed in Swedena and Denmark (Global End Date: 28 May 2019), according to European Clinical Trials Database.
21 Feb 2019 Planned End Date changed from 1 Dec 2018 to 1 Dec 2019.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com